Compliance deadlines, implementation dates and entry-into-force dates extracted from upcoming EU, UK, Swiss, Norwegian and US health regulation.
News announcement 1 October 2026 Agenda and registration - Prevention Toolkit for Children's Health and Well-being: the mental health chapter (9 October 2026) Agenda and registration - Prevention T...
07 Oct 2026 Committee for Advanced Therapies (CAT): 7-9 October 2026 European Medicines Agency, Amsterdam, the Netherlands Start date: 7 October 2026 End date: 9 October 2026
TLV approves Ultrasafe safety lancets for inclusion in Sweden's high-cost protection scheme from 12 October 2026.
TLV approves Chirana Insulin Syringe (five sizes) for inclusion in Sweden's high-cost protection scheme from 12 October 2026.
Brussels, 30 July – The EDPB and the European Commission organise a remote stakeholder event in the context of their joint work on upcoming guidelines on the interplay between competition and data ...
Next SANT committee meeting(s) will take place in Brussels on: Thursday, 15 October 2026, 9:15 - 12:00 SANT Work in progress (updated 17 September 2026) Watch SANT meetings live
Registration - EUHPP Live Webinar on Biosimilar Policies in Practice: Key Findings from the AUGMENT Study Visits (19 October 2026, 9.00-10.00 CEST)
Fixed penalty notice amounts for tobacco, vaping and nicotine product offences change from 29 October 2026 and 1 January 2027.
Vending machines for tobacco, herbal smoking products, cigarette papers, vaping and nicotine products banned from 29 October 2026.
Age of sale rules and related regulations for tobacco and herbal smoking products change from 29 October 2026 and 1 January 2027.
Age of sale rules and related regulations for vaping and nicotine products change from 29 October 2026.
Call for nominations to the Multi-stakeholder Platform Advisory Group, open until 30 October 2026, to improve the clinical trials environment.
EDPB adopts final guidelines on anonymisation, web scraping for generative AI, and personal data processing through blockchain technologies.
Monovalent veterinary vaccines against IBR, PIF and rabies must obtain an OBPR certificate before release and marketing in Spain from 1 November 2026.
International campaign #MedSafetyWeek running 2–8 November 2026 to raise awareness of adverse drug reaction reporting.
TÉMA: Zdravotnické prostředky v každodenní praxi zdravotnického zařízení | Datum konání: 3. 11. 2026 9:00–15:00 | prezenčně – opakování semináře z roku 2026, který je určený poskytovatelům bez před...
EDPB adopts guidelines on administrative fines under GDPR and on interplay between Digital Service Act and GDPR.
From 15 November 2026, Swissmedic will require active substances listed in establishment licences and GMP certificates to be pre-registered in the EMA's Substance Management Services database.
News announcement 6 October 2026 Registration - European Biotech Clusters: Connect. Collaborate. Scale: Turning the Biotech Act’s ambition into action (19 November 2026) Registration - European Bio...
Free online event featuring recent recommendations, expert exchanges, and sessions on AI deployment in healthcare contexts.
EMA sets submission deadlines for type I variations in 2026: 20 November for type IA and super-groupings, 30 November for type IB variations.
Register now for the IQWiG Autumn Symposium on 20 November 2026 in Cologne! Cost pressures within the health care system are mounting, making the issue of low-value care all the more pressing: but ...
A new Safety Module in CTIS will launch on 28 September 2026, with a two-month transition period ending 30 November 2026.
Directive clarifies 'product' definition to include digital manufacturing files and software, modernizing liability framework for AI-enabled devices and SaMD.
SUKL invites expert feedback on the third edition of the Slovak Pharmaceutical Codex, which entered into force on 15 July 2026, to identify gaps and user expectations.
MHRA will deliver first-wave regulatory assessment of qualifying Phase 1 trial applications within 14 calendar days by end of 2026.
MHRA pilot programme to deliver first-wave regulatory assessment of qualifying Phase 1 applications within 14 calendar days by end of 2026.
IQWiG notes linvoseltamab received conditional marketing authorisation in April 2025 but comparative evidence is lacking until 2026.
DEA and HHS extend telemedicine flexibilities for controlled-medication prescribing through December 31, 2026.